Skip to Main Content
Welcome to the Scientist.com Marketplace

Go to Main Navigation

18515

Ciprofibrate

Cayman Chemical

Thumbnail image

DETAILS

  • Inchi: InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)
  • Purity: ≥98%
  • Raptas: Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Cancer|Cell Cycle|G2/S||Research Area|Cardiovascular System|Lipids & Lipoproteins||Research Area|Endocrinology & Metabolism|Hormones & Receptors|PPARs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias
  • Smiles: ClC1(Cl)CC1C2=CC=C(C=C2)OC(C)(C(O)=O)C
  • Inchikey: KPSRODZRAIWAKH-UHFFFAOYSA-N
  • Cas Number: 52214-84-3
  • Formulation: A crystalline solid
  • Storage Temp: -20
  • Shipping Temp: -20
  • Formula Markup: C13H14Cl2O3
  • Formula Weight: 289.2
  • Shelf Life Days: 1460

DESCRIPTION

An agonist of PPARα (EC50 = 0.9 µM in a transactivation assay); selective for PPARα over PPARγ and PPARδ at 300 µM; induces cell cycle arrest at the G2/M and S phases in Fao, but not HepG2, cells at 250 µM; decreases fasting plasma levels of triglycerides and increases fasting plasma glucose levels in the apolipoprotein CIII transgenic mouse model of hypertriglyceridemia at 10 mg/kg